<p>资本集团私人客户服务公司在最近向证券交易委员会的披露中表示，在第四季度减少了对安进公司（NASDAQ:AMGN - 免费报告）27.7% 的持股。该基金在此期间出售了 25,906 股后，持有 67,479 股这家医疗研究公司的股票。资本集团私人客户服务公司在安进的持股在最近的报告期末价值为 17,588,000 美元。</p>
<ul>
<li>MarketBeat 周报 – 12/2 - 12/6</li>
</ul>
<p>其他机构投资者和对冲基金最近也对该公司的持股进行了调整。Talbot Financial LLC 在第四季度将其在安进的持股增加了 5.6%。Talbot Financial LLC 目前持有 42,791 股这家医疗研究公司的股票，价值为 11,153,000 美元，此前在上个季度又增持了 2,274 股。资产顾问投资管理公司在第三季度将其在安进的持股提高了 9.0%。资产顾问投资管理公司目前持有 35,934 股这家医疗研究公司的股票，价值为 11,578,000 美元，此前在此期间又增持了 2,954 股。Ascent Wealth Partners LLC 在第四季度将其在安进的持股增加了 0.7%。Ascent Wealth Partners LLC 目前持有 9,024 股这家医疗研究公司的股票，价值为 2,352,000 美元，此前在上个季度又购买了 64 股。Principal Financial Group Inc.在第三季度将其在安进的持股提高了 6.0%。Principal Financial Group Inc.目前持有 635,172 股这家医疗研究公司的股票，价值为 204,659,000 美元，此前在此期间又购买了 35,785 股。最后，ICICI Prudential Asset Management Co Ltd 在第四季度将其在安进的持股增加了 242.2%。ICICI Prudential Asset Management Co Ltd 目前持有 23,999 股这家医疗研究公司的股票，价值为 6,255,000 美元，此前在上个季度又购买了 16,985 股。机构投资者持有该公司 76.50% 的股票。</p>
<h2>安进价格表现</h2>
<p>安进的股票在周五开盘价为 277.29 美元。该公司的债务与股本比率为 9.62，流动比率为 1.26，速动比率为 0.95。该股票的 50 日简单移动平均线为 303.04 美元，200 日简单移动平均线为 294.22 美元。该公司的市值为 1490.9 亿美元，市盈率为 36.73，PEG 比率为 2.63，贝塔值为 0.59。安进的 1 年最低价为 253.30 美元，1 年最高价为 346.85 美元。</p>
<ul>
<li>安进股票因减肥药数据下跌：反应过度还是合理？</li>
</ul>
<p>安进（NASDAQ:AMGN - 获取免费报告）最近在 2 月 4 日（星期二）发布了其财报。这家医疗研究公司报告的季度每股收益为 5.31 美元，超出市场共识预期的 5.04 美元，超出幅度为 0.27 美元。安进的净利润率为 12.24%，股本回报率为 176.32%。分析师预测，安进在当前年度的每股收益将达到 20.62 美元。</p>
<h2>安进宣布分红</h2>
<p>该公司最近还宣布了一项季度分红，将于 6 月 6 日（星期五）支付。5 月 16 日（星期五）的登记投资者将获得每股 2.38 美元的分红。该分红的除息日为 5 月 16 日（星期五）。这相当于年化分红为 9.52 美元，收益率为 3.43%。安进的分红支付比率目前为 126.09%。</p>
<h2>安进的内部买卖</h2>
<ul>
<li>2 只准备在 2025 年飙升的仿制药股票</li>
</ul>
<p>在其他安进新闻中，高级副总裁 Nancy A. Grygiel 在 2 月 5 日（星期三）出售了 1,589 股公司的股票。该股票以 304.47 美元的平均价格出售，总交易额为 483,802.83 美元。交易后，这位高级副总裁现在直接持有 7,210 股公司的股票，价值约为 2,195,228.70 美元。此次交易使其持股减少了 18.06%。该出售在向证券交易委员会提交的文件中披露，相关文件可通过 SEC 网站访问。此外，执行副总裁 David M. Reese 在 2 月 21 日（星期五）出售了 25,225 股公司的股票。该股票以 304.44 美元的平均价格出售，总交易额为 7,679,499.00 美元。交易完成后，这位执行副总裁现在直接持有 36,922 股公司的股票，价值约为 11,240,533.68 美元。这代表其持股减少了 40.59%。该出售的披露信息可以在此找到。内部人士在过去 90 天内出售了 69,341 股公司股票，价值为 20,644,335 美元。内部人士持有公司 0.69% 的股票。</p>
<h2>分析师评级变动</h2>
<p>安进最近成为几份研究报告的主题。Piper Sandler Companies 在 1 月 2 日（星期四）的研究报告中重申了对安进股票的 “增持” 评级，并给出了 310.00 美元的目标价。花旗集团在 2 月 5 日（星期三）的报告中重申了对安进股票的 “中性” 评级。美国银行在 3 月 5 日（星期三）将安进股票的目标价从 275.00 美元上调至 294.00 美元，并给予该股票 “跑输大盘” 的评级。Piper Sandler 在 2 月 10 日（星期一）将安进股票的目标价从 310.00 美元上调至 329.00 美元，并给予该公司 “增持” 评级。最后，富国银行在 2 月 5 日（星期三）的研究报告中重申了对安进股票的 “持平” 评级。两位投资分析师对该股票给予了卖出评级，九位给予了持有评级，十二位给予了买入评级，一位给予了强烈买入评级。根据 MarketBeat.com 的数据，该公司目前的共识评级为 “适度买入”，共识目标价为 314.91 美元。</p>
<p><strong>查看我们关于安进的最新报告</strong></p>
<h2>关于安进</h2>
<p>（免费报告）</p>
<p>安进公司在全球范围内发现、开发、制造和提供人类治疗药物。公司的主要产品包括用于治疗斑块型银屑病、类风湿性关节炎和银屑病关节炎的恩利昔（Enbrel）；用于治疗成人斑块型银屑病、银屑病关节炎和与贝赫切特病相关的口腔溃疡的奥特兹拉（Otezla）；用于治疗绝经后女性骨质疏松症的普利亚（Prolia）；用于预防骨骼相关事件的 XGEVA；可降低心肌梗死、中风和冠状动脉再血管化风险的 Repatha；用于治疗免疫性血小板减少症患者的 Nplate；用于治疗复发性或难治性多发性骨髓瘤患者的 KYPROLIS；用于治疗红细胞数量低于正常水平和贫血的 Aranesp；用于治疗绝经后男性和女性骨质疏松症的 EVENITY；用于治疗野生型 RAS 转移性结直肠癌患者的 Vectibix；用于治疗急性淋巴细胞白血病患者的 BLINCYTO；用于治疗甲状腺眼病的 TEPEZZA；以及用于治疗慢性难治性痛风的 KRYSTEXXA。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们更看好的股票，胜过安进</li>
<li>市值计算器：如何计算市值</li>
<li>3 只中型股到大型股宣布了重大回购</li>
<li>投资者如何找到最佳的便宜股息股票</li>
<li>这 3 只股票在过去 12 个月中为股东带来了巨大的收益</li>
<li>如何开始投资房地产</li>
<li>知名对冲基金收购 HPE 的巨大股份：现在值得买入吗？</li>
</ul>
<p><strong>想看看其他对冲基金持有的 AMGN 股票吗？</strong> 请访问 HoldingsChannel.com，获取安进公司（NASDAQ:AMGN - 免费报告）的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1HTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1HTg"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在安进吗？</h2>
<p>在考虑安进之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前买入……而安进并不在名单上。</p>
<p>虽然安进目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

安进

<p>Capital Group Private Client Services Inc. 在第四季度减少了对安进（Amgen Inc.，NASDAQ:AMGN）27.7% 的持股，出售了 25,906 股，剩余 67,479 股，市值为 1,759 万美元。其他机构投资者也调整了他们的持仓，Talbot Financial LLC 增加了 5.6% 的持股。安进的股票开盘价为 277.29 美元，市值为 1,490.9 亿美元，市盈率为 36.73。该公司最近宣布每股季度股息为 2.38 美元，收益率为 3.43%</p>

<p>Capital Group Private Client Services Inc. lessened its position in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 27.7% in the fourth quarter, according to its most recent disclosure with the Securities &amp; Exchange Commission. The fund owned 67,479 shares of the medical research company's stock after selling 25,906 shares during the period. Capital Group Private Client Services Inc.'s holdings in Amgen were worth $17,588,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>资本集团私人客户服务公司在最近向证券交易委员会的披露中表示，在第四季度减少了对安进公司（NASDAQ:AMGN - 免费报告）27.7% 的持股。该基金在此期间出售了 25,906 股后，持有 67,479 股这家医疗研究公司的股票。资本集团私人客户服务公司在安进的持股在最近的报告期末价值为 17,588,000 美元。</p>
</div><ul>
<li>MarketBeat Week in Review – 12/2 - 12/6</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 周报 – 12/2 - 12/6</li>
</ul>
</div><p>Other institutional investors and hedge funds also recently made changes to their positions in the company. Talbot Financial LLC increased its position in shares of Amgen by 5.6% during the fourth quarter. Talbot Financial LLC now owns 42,791 shares of the medical research company's stock worth $11,153,000 after acquiring an additional 2,274 shares in the last quarter. Asset Advisors Investment Management LLC raised its stake in Amgen by 9.0% in the 3rd quarter. Asset Advisors Investment Management LLC now owns 35,934 shares of the medical research company's stock valued at $11,578,000 after acquiring an additional 2,954 shares during the period. Ascent Wealth Partners LLC increased its stake in shares of Amgen by 0.7% in the fourth quarter. Ascent Wealth Partners LLC now owns 9,024 shares of the medical research company's stock worth $2,352,000 after purchasing an additional 64 shares in the last quarter. Principal Financial Group Inc. boosted its holdings in Amgen by 6.0% in the 3rd quarter. Principal Financial Group Inc. now owns 635,172 shares of the medical research company's stock worth $204,659,000 after buying an additional 35,785 shares during the period. Finally, ICICI Prudential Asset Management Co Ltd grew its stake in Amgen by 242.2% in the 4th quarter. ICICI Prudential Asset Management Co Ltd now owns 23,999 shares of the medical research company's stock valued at $6,255,000 after buying an additional 16,985 shares in the last quarter. Institutional investors own 76.50% of the company's stock.</p>
<div class="lb-trans"><p>其他机构投资者和对冲基金最近也对该公司的持股进行了调整。Talbot Financial LLC 在第四季度将其在安进的持股增加了 5.6%。Talbot Financial LLC 目前持有 42,791 股这家医疗研究公司的股票，价值为 11,153,000 美元，此前在上个季度又增持了 2,274 股。资产顾问投资管理公司在第三季度将其在安进的持股提高了 9.0%。资产顾问投资管理公司目前持有 35,934 股这家医疗研究公司的股票，价值为 11,578,000 美元，此前在此期间又增持了 2,954 股。Ascent Wealth Partners LLC 在第四季度将其在安进的持股增加了 0.7%。Ascent Wealth Partners LLC 目前持有 9,024 股这家医疗研究公司的股票，价值为 2,352,000 美元，此前在上个季度又购买了 64 股。Principal Financial Group Inc.在第三季度将其在安进的持股提高了 6.0%。Principal Financial Group Inc.目前持有 635,172 股这家医疗研究公司的股票，价值为 204,659,000 美元，此前在此期间又购买了 35,785 股。最后，ICICI Prudential Asset Management Co Ltd 在第四季度将其在安进的持股增加了 242.2%。ICICI Prudential Asset Management Co Ltd 目前持有 23,999 股这家医疗研究公司的股票，价值为 6,255,000 美元，此前在上个季度又购买了 16,985 股。机构投资者持有该公司 76.50% 的股票。</p>
</div><h2>Amgen Price Performance</h2>
<div class="lb-trans"><h2>安进价格表现</h2>
</div><p>AMGN opened at $277.29 on Friday. The company has a debt-to-equity ratio of 9.62, a current ratio of 1.26 and a quick ratio of 0.95. The stock's 50 day simple moving average is $303.04 and its 200 day simple moving average is $294.22. The firm has a market cap of $149.09 billion, a price-to-earnings ratio of 36.73, a PEG ratio of 2.63 and a beta of 0.59. Amgen Inc. has a 1 year low of $253.30 and a 1 year high of $346.85.</p>
<div class="lb-trans"><p>安进的股票在周五开盘价为 277.29 美元。该公司的债务与股本比率为 9.62，流动比率为 1.26，速动比率为 0.95。该股票的 50 日简单移动平均线为 303.04 美元，200 日简单移动平均线为 294.22 美元。该公司的市值为 1490.9 亿美元，市盈率为 36.73，PEG 比率为 2.63，贝塔值为 0.59。安进的 1 年最低价为 253.30 美元，1 年最高价为 346.85 美元。</p>
</div><ul>
<li>Amgen Stock Falls on Weight Loss Drug Data: Overreaction or Fair?</li>
</ul>
<div class="lb-trans"><ul>
<li>安进股票因减肥药数据下跌：反应过度还是合理？</li>
</ul>
</div><p>Amgen (NASDAQ:AMGN - Get Free Report) last issued its earnings results on Tuesday, February 4th. The medical research company reported $5.31 EPS for the quarter, topping the consensus estimate of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. As a group, analysts predict that Amgen Inc. will post 20.62 earnings per share for the current year.</p>
<div class="lb-trans"><p>安进（NASDAQ:AMGN - 获取免费报告）最近在 2 月 4 日（星期二）发布了其财报。这家医疗研究公司报告的季度每股收益为 5.31 美元，超出市场共识预期的 5.04 美元，超出幅度为 0.27 美元。安进的净利润率为 12.24%，股本回报率为 176.32%。分析师预测，安进在当前年度的每股收益将达到 20.62 美元。</p>
</div><h2>Amgen Announces Dividend</h2>
<div class="lb-trans"><h2>安进宣布分红</h2>
</div><p>The firm also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Friday, May 16th will be issued a dividend of $2.38 per share. The ex-dividend date of this dividend is Friday, May 16th. This represents a $9.52 dividend on an annualized basis and a yield of 3.43%. Amgen's dividend payout ratio is presently 126.09%.</p>
<div class="lb-trans"><p>该公司最近还宣布了一项季度分红，将于 6 月 6 日（星期五）支付。5 月 16 日（星期五）的登记投资者将获得每股 2.38 美元的分红。该分红的除息日为 5 月 16 日（星期五）。这相当于年化分红为 9.52 美元，收益率为 3.43%。安进的分红支付比率目前为 126.09%。</p>
</div><h2>Insider Buying and Selling at Amgen</h2>
<div class="lb-trans"><h2>安进的内部买卖</h2>
</div><ul>
<li>2 Generic Drug Stocks Ready to Surge in 2025</li>
</ul>
<div class="lb-trans"><ul>
<li>2 只准备在 2025 年飙升的仿制药股票</li>
</ul>
</div><p>In other Amgen news, SVP Nancy A. Grygiel sold 1,589 shares of the business's stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total transaction of $483,802.83. Following the transaction, the senior vice president now directly owns 7,210 shares of the company's stock, valued at approximately $2,195,228.70. The trade was a 18.06 % decrease in their position. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which can be accessed through the SEC website. Also, EVP David M. Reese sold 25,225 shares of the firm's stock in a transaction dated Friday, February 21st. The stock was sold at an average price of $304.44, for a total transaction of $7,679,499.00. Following the completion of the sale, the executive vice president now directly owns 36,922 shares of the company's stock, valued at approximately $11,240,533.68. This represents a 40.59 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 69,341 shares of company stock valued at $20,644,335 in the last 90 days. Insiders own 0.69% of the company's stock.</p>
<div class="lb-trans"><p>在其他安进新闻中，高级副总裁 Nancy A. Grygiel 在 2 月 5 日（星期三）出售了 1,589 股公司的股票。该股票以 304.47 美元的平均价格出售，总交易额为 483,802.83 美元。交易后，这位高级副总裁现在直接持有 7,210 股公司的股票，价值约为 2,195,228.70 美元。此次交易使其持股减少了 18.06%。该出售在向证券交易委员会提交的文件中披露，相关文件可通过 SEC 网站访问。此外，执行副总裁 David M. Reese 在 2 月 21 日（星期五）出售了 25,225 股公司的股票。该股票以 304.44 美元的平均价格出售，总交易额为 7,679,499.00 美元。交易完成后，这位执行副总裁现在直接持有 36,922 股公司的股票，价值约为 11,240,533.68 美元。这代表其持股减少了 40.59%。该出售的披露信息可以在此找到。内部人士在过去 90 天内出售了 69,341 股公司股票，价值为 20,644,335 美元。内部人士持有公司 0.69% 的股票。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>AMGN has been the subject of several recent research reports. Piper Sandler Companies reiterated an &#34;overweight&#34; rating and issued a $310.00 price target on shares of Amgen in a research report on Thursday, January 2nd. Citigroup reissued a &#34;neutral&#34; rating on shares of Amgen in a report on Wednesday, February 5th. Bank of America upped their target price on shares of Amgen from $275.00 to $294.00 and gave the stock an &#34;underperform&#34; rating in a report on Wednesday, March 5th. Piper Sandler boosted their price target on shares of Amgen from $310.00 to $329.00 and gave the company an &#34;overweight&#34; rating in a research report on Monday, February 10th. Finally, Wells Fargo &amp; Company reiterated an &#34;equal weight&#34; rating on shares of Amgen in a research report on Wednesday, February 5th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $314.91.</p>
<div class="lb-trans"><p>安进最近成为几份研究报告的主题。Piper Sandler Companies 在 1 月 2 日（星期四）的研究报告中重申了对安进股票的 “增持” 评级，并给出了 310.00 美元的目标价。花旗集团在 2 月 5 日（星期三）的报告中重申了对安进股票的 “中性” 评级。美国银行在 3 月 5 日（星期三）将安进股票的目标价从 275.00 美元上调至 294.00 美元，并给予该股票 “跑输大盘” 的评级。Piper Sandler 在 2 月 10 日（星期一）将安进股票的目标价从 310.00 美元上调至 329.00 美元，并给予该公司 “增持” 评级。最后，富国银行在 2 月 5 日（星期三）的研究报告中重申了对安进股票的 “持平” 评级。两位投资分析师对该股票给予了卖出评级，九位给予了持有评级，十二位给予了买入评级，一位给予了强烈买入评级。根据 MarketBeat.com 的数据，该公司目前的共识评级为 “适度买入”，共识目标价为 314.91 美元。</p>
</div><p><strong>Check Out Our Latest Report on Amgen</strong></p>
<div class="lb-trans"><p><strong>查看我们关于安进的最新报告</strong></p>
</div><h2>About Amgen</h2>
<div class="lb-trans"><h2>关于安进</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.</p>
<div class="lb-trans"><p>安进公司在全球范围内发现、开发、制造和提供人类治疗药物。公司的主要产品包括用于治疗斑块型银屑病、类风湿性关节炎和银屑病关节炎的恩利昔（Enbrel）；用于治疗成人斑块型银屑病、银屑病关节炎和与贝赫切特病相关的口腔溃疡的奥特兹拉（Otezla）；用于治疗绝经后女性骨质疏松症的普利亚（Prolia）；用于预防骨骼相关事件的 XGEVA；可降低心肌梗死、中风和冠状动脉再血管化风险的 Repatha；用于治疗免疫性血小板减少症患者的 Nplate；用于治疗复发性或难治性多发性骨髓瘤患者的 KYPROLIS；用于治疗红细胞数量低于正常水平和贫血的 Aranesp；用于治疗绝经后男性和女性骨质疏松症的 EVENITY；用于治疗野生型 RAS 转移性结直肠癌患者的 Vectibix；用于治疗急性淋巴细胞白血病患者的 BLINCYTO；用于治疗甲状腺眼病的 TEPEZZA；以及用于治疗慢性难治性痛风的 KRYSTEXXA。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Amgen</li>
<li>Market Cap Calculator: How to Calculate Market Cap</li>
<li>3 Mid-Cap to Mega-Cap Stocks Have Announced Significant Buybacks</li>
<li>How Investors Can Find the Best Cheap Dividend Stocks</li>
<li>These 3 Stocks Have Huge Last 12 Months Shareholder Yields</li>
<li>How to Start Investing in Real Estate</li>
<li>Prominent Hedge Fund Acquires Huge Stake in HPE: Is It a Buy Now?</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过安进</li>
<li>市值计算器：如何计算市值</li>
<li>3 只中型股到大型股宣布了重大回购</li>
<li>投资者如何找到最佳的便宜股息股票</li>
<li>这 3 只股票在过去 12 个月中为股东带来了巨大的收益</li>
<li>如何开始投资房地产</li>
<li>知名对冲基金收购 HPE 的巨大股份：现在值得买入吗？</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding AMGN?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对冲基金持有的 AMGN 股票吗？</strong> 请访问 HoldingsChannel.com，获取安进公司（NASDAQ:AMGN - 免费报告）的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1HTg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=AMGN"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Amgen Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在安进吗？</h2>
</div><p>Before you consider Amgen, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑安进之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amgen wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前买入……而安进并不在名单上。</p>
</div><p>While Amgen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然安进目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Capital Group Private Client Services Inc. 出售了 25,906 股安进公司（NASDAQ:AMGN）的股票